Shots:
- The US has approved Sarclisa Escena (isatuximab-irfc; SC) + SoC for the treatment of pts with MM across all existing indications of Sarclisa IV formulation
- Approval was backed by multiple trials, incl. P-III (IRAKLIA) in R/R MM, which showed shorter treatment time & fewer infusion-related reactions with Sarclisa Escena
- In IRAKLIA, SC Sarclisa delivered via Enable Injections’ enFuse OBI in combination with pomalidomide & dexamethasone achieved a 71.1% ORR vs 70.5% with IV Sarclisa-Pd, meeting the non-inferiority in adults with R/R MM who had received ≥1L of treatment
Ref: Sanofi | Image: Sanofi | Press Release
Related News: Sanofi Reports P-III (Baby-COMET) Trial Data on Nexviazyme for Infantile-Onset Pompe Disease (IOPD)
PharmaShots, your go-to media platform for customized news ranging across multiple indications. For more information, connect with us at connect@pharmashots.com
